Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis - Report - MDSpire
Advertisement
Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis
Clinical Report: Safety and Effectiveness of Sacubitril/Valsartan in STEMI
Overview
This study evaluates the safety and efficacy of sacubitril/valsartan versus benazepril in STEMI patients with mid-range left ventricular ejection fraction (LVEF). Initial treatment with sacubitril/valsartan demonstrated superior efficacy in improving cardiac systolic function without significant differences in safety outcomes.
Background
ST-segment elevation myocardial infarction (STEMI) can lead to heart failure, particularly in patients with mid-range LVEF, which is an area of limited research. Effective pharmacological strategies for this population are critical, as they are at risk for poor long-term outcomes. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has shown promise in improving cardiac function in heart failure patients, warranting investigation in the context of STEMI.
Data Highlights
Parameter
S/V Group
Benazepril Group
Reduction in LVESV
Significant
Not Significant
Improvement in LVEF
Significant
Not Significant
Improvement in GLS
Significant
Not Significant
Incidence of MACE
No Significant Difference
No Significant Difference
Key Findings
Initial treatment with sacubitril/valsartan resulted in greater reductions in left ventricular end-systolic volume compared to benazepril.
Patients receiving sacubitril/valsartan showed significant improvements in left ventricular ejection fraction and global longitudinal strain after one month.
No significant differences were observed in the incidence of major adverse cardiac events between the two treatment groups.
The study utilized propensity score matching to balance baseline characteristics, enhancing the validity of the findings.
These results suggest potential benefits of sacubitril/valsartan in improving cardiac function in STEMI patients with mid-range LVEF.
Clinical Implications
Clinicians may consider sacubitril/valsartan as a viable initial treatment option for STEMI patients with mid-range LVEF, given its efficacy in improving cardiac function. However, ongoing monitoring for safety and long-term outcomes is essential, as current guidelines do not yet endorse routine use of this therapy immediately post-MI.
Conclusion
Sacubitril/valsartan demonstrates superior efficacy in enhancing cardiac systolic function in STEMI patients with mid-range LVEF compared to benazepril, with comparable safety profiles. Further research is needed to validate these findings in larger cohorts.
